FDA Course Unlikely to Change Under Eschenbach's Direction, Observers Say

Drug Industry Daily
KEYWORDS FDA
A A

Acting FDA Commissioner Andrew von Eschenbach is unlikely to have much effect on the agency's agenda, as the FDA's existing division heads will continue to drive policy decisions, according to various stakeholders. However, these same sources said the continuous turnover in leadership at the FDA may tarnish the agency's credibility.

To View This Article:

Login

Subscribe To Drug Industry Daily